8th Annual MarketsandMarkets

Biomarker and Companion Diagnostics Conference

8th - 9th February 2023

Double Tree by Hilton, San Diego - Mission Valley

Leveraging next gen technologies beyond conventional biomarker drug discovery!

MarketsandMarkets bring to you the 8th Annual Biomarker and CDx Conference scheduled to be held on 8th - 9th February 2023 in San Diego, USA. This event will have an introduction to turning biomarkers into companion diagnostics.

30+ experts from academia and industry will be presenting their current work in Biomarkers, Latest updates on regulatory guidelines and approvals, Cancer biomarker validation for clinical application, Biomarkers and Personalized Medicine, Impact of Big data in translational biomarker research and Future of Companion Diagnostics
Opportunity to develop long-lasting business relationships and networking opportunities with researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies, Universities, and Research institutes.
Over 20 presentations, round-tables, and panel discussions focused on the key opportunities and challenges in biomarker research, from precision medicine and companion diagnostics through to digital biomarkers and clinical trials.

The Expert Panel will take you through their presentations which will include problems, solutions and services in the Clinical Applications of Biomarkers in Immuno-Oncology, Neurology and Inflammatory Diseases. Attendees would evidence the examples and the case studies which will help in creating the revenue. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers.

CO-LOCATED CONFERENCES

WHAT TO EXPECT

  • Commercialization of CDx
  • Proteomics and Genomics based Biomarkers
  • Biomarker Drug Discovery and Assay Development
  • Multiplex Companion Diagnostics and Regulatory Guidelines
  • Design of clinical trials in CDx
  • Digital Biomarkers, Predictive Biomarkers, Precision Medicine and Big Data
  • Clinical Applications of Biomarkers in Immuno-Oncology, Neurology and Inflammatory Diseases

Researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies & Universities and Research institutes working in:

  • Biomarker discovery/development
  • Translational research
  • Clinical Biomarker
  • Biomarkers in IO and Neurological disorders
  • Imaging Biomarkers
  • Pathology
  • Companion Diagnostics
  • Biomarker Imaging
  • Proteomics Biomarkers
  • Experimental Medicine
  • Data Science
  • Biomarkers in Clinical Discovery
  • Immuno-oncology/Neuroscience Drug Discovery
  • Diagnostic Biomarkers development
  • Personalized Medicine
  • Immunology Biomarkers

CONFERENCE AGENDA

Registration

08:15 - 08:45

Welcome note from MarketsandMarkets

Nikita Parab

Nikita Parab, Associate Director, Conferences, MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairman

Manish Kohli

Manish Kohli, Professor, Huntsman Cancer Institute, University of Utah

08:55 - 09:00

Development of a Kit-Based Assay for Assessing Homologous Recombination Deficiency (HRD) in Ovarian Cancer

Amy Wehn

Amy Wehn, Director, Companion Diagnostics, Merck

09:00 - 09:30

Challenges associated with Clinical Biomarker Validation

End-to-end proteomics services for discovery, validation and deployment of novel biomarkers in drug development and clinical trials

Ian Pike

Ian Pike, Chief Scientific Officer, Proteome Sciences PLC

09:30 - 10:00

Develop and Validate Cancer Methylation Panel Using Targeted Bisulfite NGS

Liying Yan

Liying Yan, President, EpigenDx

10:00 - 10:25

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Delivering CDx Excellence: Innovation and Partnerships

Deboleena Sarkar

Deboleena Sarkar, Director Companion Diagnostics Business Development, Qiagen

11:15 - 11:45

BD Biosciences Advancing CDx and clinical trial assay development using flow cytometry

Scott Bornheimer

Scott Bornheimer , Associate Director, Medical & Scientific Affairs , BD Biosciences

11:45 - 12:15

Current and Future Liquid Biopsy Landscapes in Advanced Prostate cancer: Implications for Clinical Practice

Manish Kohli

Manish Kohli, Professor, Huntsman Cancer Institute, University of Utah

12:15 - 12:45

Turning preclinical findings into clinic-ready biomarker assays to support the phase I/II of BT7480, a Bicycle tumor-targeted immune cell agonist®

Heather Cohen

Heather Cohen, Director, Translational Sciences, Bicycle Therapeutics

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

Role of Biomarkers in Personalized Medicine

Precision Oncology Centric Development of Antibody Drug Conjugates

Rakesh Dixit

Rakesh Dixit, CEO, Bionavigen

14:15 - 14:45

T-cell engagers in immuno-oncology: challenges and advances in biomarker-driven clinical approaches

Majid Ghoddusi

Majid Ghoddusi , Senior Director, Clinical Biomarkers, Poseida Therapeutics

14:45 - 15:15

Design of a comprehensive liquid biopsy assay to monitor real-time anti-tumor response in patients receiving an individualized neoantigen cancer vaccine

Desiree Schenk

Desiree Schenk, Principal Scientist, Gritstone Oncology

15:15 - 15:45

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:45 - 16:30

Panel Discussion:

16:30 - 17:00

Innovation strategy for the most disruptive, turbulent, and transformative period in modern history. Thriving in the rapidly evolving field of precision medicine

George Pell

George Pell, CEO and Founder, Thirty-Six

17:00 - 17:30

Closing Remarks from the Chairperson

Manish Kohli

Manish Kohli, Professor, Huntsman Cancer Institute, University of Utah

17:30 - 17:55

Drinks Reception & Networking

17:35 - 17:35

End of Day 1

17:35 - 17:35

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairman

George Pell

George Pell, CEO and Founder, Thirty-Six

08:55 - 09:00

State investment in precision medicine research that addresses health disparities

Shannon Muir

Shannon Muir, Co-director of the California Initiative to Advance Precision Medicine in the California Governor’s Office of Planning and Research,

09:00 - 09:30

From Biomarkers to CDx: Strategies to accelerate CDx development and Commercialization

KRAS: From Undruggable Target to CDx and Beyond

Mason Israel

Mason Israel, Regional Medical Affairs Director, Mirati Therapeutics

09:30 - 10:00

Antibody-based therapeutic and diagnostic development targeting the biological driver of tumorigenesis Progranulin.

Ginette Serrero

Ginette Serrero, Chief Executive Officer, Precision Antibody, USA

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Future of RNA Diagnostics in Cancer

Michael Milburn

Michael Milburn, President, CEO, GeneCentric Therapeutics

11:15 - 11:45

Clinical Applications of Biomarkers in Immunotherapy and Oncology

A novel molecular signature to detect, monitor and predict urothelial carcinomas

Hideki Furuya

Hideki Furuya, Assistant Professor, Cedars-Sinai Medical Center

11:45 - 12:15

Translational Pathology Biomarker Research in Targeted Protein Degradation Hematologic & Solid Tumor Programs

Maria Wang

Maria Wang, Associate Director, Bristol-Myers Squibb

12:15 - 12:45

Overcoming Resistance to CAR T Cell Therapies

John Rossi

John Rossi, Vice President, Head, Translational Medicine, , Syncopation Lifesciences

12:45 - 13:15

Closing Remarks from the Chairperson

George Pell

George Pell, CEO and Founder, Thirty-Six

13:15 - 13:20

Lunch and Poster Presentation | One-to-One Networking Meetings

13:20 - 14:20

End of Conference

14:20 - 14:20

ENQUIRE NOW

SPEAKERS

Heather Cohen

Heather Cohen

Director, Translational Sciences, Bicycle Therapeutics

Liying Yan

Liying Yan

President, EpigenDx

Hideki Furuya

Hideki Furuya

Assistant Professor, Cedars-Sinai Medical Center

Deboleena Sarkar

Deboleena Sarkar

Director Companion Diagnostics Business Development, Qiagen

Ginette Serrero

Ginette Serrero

Chief Executive Officer, Precision Antibody, USA

Manish Kohli

Manish Kohli

Professor, Huntsman Cancer Institute, University of Utah

George Pell

George Pell

CEO and Founder, Thirty-Six

Majid Ghoddusi

Majid Ghoddusi

Senior Director, Clinical Biomarkers, Poseida Therapeutics

Shannon Muir

Shannon Muir

Co-director of the California Initiative to Advance Precision Medicine in the California Governor’s Office of Planning and Research,

Amy Wehn

Amy Wehn

Director, Companion Diagnostics, Merck

Maria Wang

Maria Wang

Associate Director, Bristol-Myers Squibb

Ian Pike

Ian Pike

Chief Scientific Officer, Proteome Sciences PLC

SPONSORS

Owlstone Medical
Proteome Sciences
EpigenDx
BD Biosciences, USA
Precision Antibody
GeneCentric Therapeutics, Inc.
QIAGEN
Q2 Solutions
HTG Molecular Diagnostics, Inc.
Bio-Techne

PARTNERS

LOCATION

Venue

Double Tree by Hilton, San Diego - Mission Valley

PAST EVENT GALLERY